EHA HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSION: GMMG-HD7 TRIAL
OR
Chair
Dr. Donna Reece
Panelists
Dr. Darrell White
Dr. Maria Victoria Mateos Manteca
This program has been made possible through unrestricted support from Sanofi.
Studies/trials discussed:
- Isatuximab,lenalidomide,bortezomib, and dexamethasone for newly diagnosed transplant eligible multiple myeloma post transplantation interim analysis of the randomized phase III GMMG-HD7 trial.
